Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer

Overview of attention for article published in BMC Cancer, July 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (75th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,942 followers.

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer https://t.co/mIzB8NomvJ https://t.co/uVMU4BIbqW

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer https://t.co/orpRyCe5c3

New article: Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer https://t.co/HfTAG02WIn #lungcancer #oncology https://t.co/Glht8QsuHo

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.